<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Sandy Wright on Medium]]></title>
        <description><![CDATA[Stories by Sandy Wright on Medium]]></description>
        <link>https://medium.com/@sandywright?source=rss-d611815f6ac4------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*3hStzUlU6cmOpr_Arw4U_Q.jpeg</url>
            <title>Stories by Sandy Wright on Medium</title>
            <link>https://medium.com/@sandywright?source=rss-d611815f6ac4------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Sat, 21 Nov 2026 04:19:51 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@sandywright/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Digital Mental Health in Adults & Older People]]></title>
            <link>https://medium.com/@sandywright/digital-mental-health-in-adults-older-people-c4f19d0a6f9?source=rss-d611815f6ac4------2</link>
            <guid isPermaLink="false">https://medium.com/p/c4f19d0a6f9</guid>
            <category><![CDATA[digital-health]]></category>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[mental-health]]></category>
            <category><![CDATA[innovation]]></category>
            <category><![CDATA[technology]]></category>
            <dc:creator><![CDATA[Sandy Wright]]></dc:creator>
            <pubDate>Thu, 10 Oct 2019 05:01:01 GMT</pubDate>
            <atom:updated>2019-10-11T08:14:18.254Z</atom:updated>
            <content:encoded><![CDATA[<blockquote>The Royal Society of Medicine’s Digital Health Section holds regular meetings on the latest developments in digital health. On September 23rd 2019, attendees convened on the RSM’s home in central London to hear from thought leaders, champions, professionals and patients who are on the front line dealing with adult mental health issues. They explored the mental effects caused by the use of digital technology as well as the benefits generated from doing so. In the interests of brevity, this post doesn’t cover the full agenda of presentations. Check out the <a href="https://rsm.ac/35pNxMT">full agenda</a> and view upcoming Digital Health RSM events <a href="https://rsm.ac/2opaDCw">here</a>.</blockquote><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*H5xbc40iVkTSqKhV.jpeg" /><figcaption>The Royal Society of Medicine — 1 Wimpole Street, London</figcaption></figure><p>There is nothing more sobering than hearing someone describe how they attempted to take their own life. It is of course, a subject relevant for a mental health conference, yet perhaps rarely discussed as openly and candidly as it was on the RSM stage. Nothing illustrates the need for high quality mental health interventions than someone who has found themselves in the darkest of places. The story was delivered by Rob Stephenson, founder of <a href="https://inside-out.org/">Inside Out</a>, who’s own struggle with bipolar disorder has made him a staunch advocate of de-stigmatising mental health problems — whether that’s including his daily mental health rating in his email signature, or talking openly at conferences and events about his own experiences.</p><p>The problem, as Rob described, is that not enough workplace leaders are talking about mental health. It is an opinion that is shared by high profile individuals like Prince William, who has also called for mental health to be de-stigmatised at the <a href="https://www.theguardian.com/business/live/2019/jan/23/davos-2019-mental-health-prince-william-ardern-abe-merkel-qisham-live">World Economic Forum in Davos</a>. Rob’s organisation aims to help dismantle the stigma around mental health in the workplace. In March this year they published a list of senior leaders across industries who were willing to speak out about their lived experiences with poor mental health. Alongside this they’ve produced a mental health charter that companies can adopt in order to demonstrate that mental wellbeing is a high priority within their organisation.</p><p>His talk set the scene for a conference that wouldn’t focus so much on the relationship between digital technology and user, but more the acquisition and adoption of these technologies by institutions and companies for the benefit of employees and patients. It is perhaps uncomfortable to think about the ‘cost’ of lost productivity due to an employee’s poor state of physical or mental health. However we might consider this corporate language acceptable if it supports the scale-up of worthwhile digital interventions.</p><p>Of course the wellbeing of employees should be as important to companies as the generation of shareholder value. But there is also a strong business case to address the issue of poor mental health amongst employees. With mental health problems affecting <a href="https://www.mind.org.uk/information-support/types-of-mental-health-problems/statistics-and-facts-about-mental-health/how-common-are-mental-health-problems/#.XZzu9udKi_I">1 in 4</a> individuals each year in the UK, and 50% of issues becoming established by as early as age 14, the cost to businesses per employee is around <a href="https://www.centreformentalhealth.org.uk/news/mental-health-problems-work-cost-uk-economy-ps349bn-last-year-says-centre-mental-health">£1300</a>. Someone who is mentally unwell but still able to physically be at work is unable to flourish and be productive. This concept of ‘presenteeism’ makes a up a large part of the cost for employers and is rife across a variety of industries and sectors.</p><p>Of course, the first step in seeking help for a mental health issue is admitting there’s a problem in the first place. But according to <a href="https://medium.com/@marcusfgardiner">Marcus Gardiner</a>, software developer at Softwire, 89% of workers don’t feel able to disclose mental ill health to a manager and will often go five or more years before seeking any form of treatment. Shocked by the extent of the problem he travelled the world, through a Winston Churchill Memorial Trust research grant, seeking out academics, startups and universities involved in digital mental health care.</p><p>He quickly found that there was an abundance of solutions that, through the virtue of being digital, were anonymous, scalable, cost effective and accessible. Some, such as digital CBT, had even demonstrated similar efficacy to in-person therapies. He categorised his findings based on the shared characteristics of the products he discovered, which included gateways and portals (<a href="https://www.mind.org.uk/">Mind</a>), wellbeing platforms (<a href="https://www.silvercloudhealth.com/uk">Silvercloud</a>), teletherapies (<a href="https://dr-julian.com/about-us/therapies/cognitive-behavioural-therapy-cbt/">Dr Julian</a>), wearables (<a href="https://www.myfeel.co/">Feel</a>), screening therapies (<a href="https://www.moodscope.com/">Moodscope</a>) and peer support platforms (<a href="https://www.sharon.nhs.uk/">SHaRON</a>).</p><p>Yet despite their abundance, as with many digital products, the key to adoption is dependent on several important factors. Firstly, trust is essential. Not only do digital mental health products need to ensure user data is appropriately processed and protected (see my article <a href="https://medium.com/@sandywright/health-data-who-owns-it-d083a9d1d3d4">here</a> on health data), they need to be inherently trustworthy companies in order to convince users to be open about conditions that still hold a great deal of stigma. Secondly, they need to establish a positive return on investment. As mentioned above, for companies to adopt a new service or technology, they need to rationalise it as a financial investment and not a cost. Although this is somewhat de-humanising in the context of mental health services, it is a hard truth that any new medical innovation, mental health related or otherwise, must accept. Thirdly, it is imperative that user engagement with these products is sustained. Clinical efficacy is predicated on recurrent use of these tools. Although we may feel uncomfortable with the techniques used by the likes of Instagram and Facebook to increase our consumption of their products, perhaps the psychological tools they employ to drive engagement have a more ethical application in the context of mental health products.</p><p>Marcus suggested that digital mental healthcare, having reached a position where it can demonstrate excellent educational and signposting capabilities, now needed to evolve to the next level of providing a digital end-to-end experience — including screening, diagnosis, referral and treatment. To reach this next level of integrated mental healthcare however, the plethora of digital products available need to be credible and reliable tools for those with poor mental health.</p><p>Perhaps we are too quick to credit mental healthcare products with a firm stamp of a approval. We live in a world of evidence based medicine, yet Lloyd Humphreys and Colette Bird from Silvercloud emphasised how only 3% of mental health apps are actually evidence based. The rest are more ‘evidence informed’. They also made the assertion that 81% of mental apps only target a single mental health disorder. The approach at Silvercloud — a digital mental health platform — is to take a more blended approach. They offer flexible delivery models including population based, self help, coached and face-to-face models. Perhaps this is the right approach, particularly when <a href="https://www.mind.org.uk/news-campaigns/news/40-per-cent-of-all-gp-appointments-about-mental-health/">40%</a> of GP appointments are due to mental health issues and <a href="https://fullfact.org/health/mental-health-spending-england/">14%</a> of all NHS spend is mental health related. A personalised approach to these problems will go some way to ensure users receive the right treatment at the right time.</p><p>We often assume that innovation in healthcare is led by the private sector. Yet the most successful digital transformation project of recent times actually took place within the NHS. The Improving Access to Psychological Therapies <a href="https://www.england.nhs.uk/mental-health/adults/iapt/">(IAPT)</a> programme began in 2008 and has transformed the treatment of adult anxiety disorders and depression in England. Not only is it providing mental healthcare to over 1 million patients per year, it has trained a whole new workforce, changed clinical pathways, embedded both digital and therapeutic approaches, and achieved high recovery rates.</p><p>All the therapies offered through IAPT are evidence based, patient’s outcomes are monitored and the therapist’s outcomes are tracked too in order to support the continual improvement of their practice. The service is to start integrating with physical health services in order to better manage patients with concomitant mental health and long term conditions. By 2024 the IAPT programme hopes to support 1.9 million adults each year.</p><p>I wrote in a <a href="https://medium.com/@sandywright/19th-medical-innovations-summit-7a4f93783376">previous article</a> about how our perception of ‘innovation’ can lead us to assume digital is the only means through which we can achieve true innovation. Perhaps we also assume that the NHS is unable to implement digital technologies at the scale of private, more agile private companies. There is no doubt that the tools listed above, whether they are wellbeing platforms, new forms of wearable technology or innovative teletherapies will have a positive impact on the overall ecosystem of mental healthcare technologies available to individuals, companies and health providers. But much like the ‘sustained use’ a digital mental health product requires from it’s user in order to be effective, the NHS has demonstrated that a sustained effort to overhaul mental health service in this country has led to a step change in the quality of mental healthcare. The core tenants of evidence based therapies, routine outcome monitoring and outcomes focussed supervision should be adopted by those companies and tools which aim to replicate IAPT’s success.</p><p>If you enjoyed this article and want to get in touch, find me on Twitter <a href="http://twitter.com/sandycewright">@SandyCEWright</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=c4f19d0a6f9" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[19th Medical Innovations Summit]]></title>
            <link>https://medium.com/@sandywright/19th-medical-innovations-summit-7a4f93783376?source=rss-d611815f6ac4------2</link>
            <guid isPermaLink="false">https://medium.com/p/7a4f93783376</guid>
            <category><![CDATA[medtech]]></category>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[artificial-intelligence]]></category>
            <category><![CDATA[innovation]]></category>
            <dc:creator><![CDATA[Sandy Wright]]></dc:creator>
            <pubDate>Tue, 01 Oct 2019 21:13:42 GMT</pubDate>
            <atom:updated>2019-10-02T21:14:06.758Z</atom:updated>
            <content:encoded><![CDATA[<h3>The 19th Medical Innovations Summit</h3><h4>Royal Society of Medicine</h4><blockquote>The Royal Society of Medicine’s <a href="https://t.co/WsZMNMeH1h?amp=1">Medical Innovations Summit</a> provides a biannual platform for the presentation and discussion of inspirational ideas and developments in the field of medicine and healthcare, bringing together clinicians, entrepreneurs, policy-makers and VCs. Below is a summary of a selection of talks, presentations and discussions that took place during the event. In the interests of brevity, this post doesn’t cover the full agenda of presentations. Check out upcoming RSM events <a href="https://rsm.ac/2opaDCw">here</a>.</blockquote><figure><img alt="" src="https://cdn-images-1.medium.com/max/1000/1*EP0In0ZV-QizuO7kQ42Gjw.jpeg" /></figure><p>In recent times, the word ‘innovation’ has become inextricably linked to digital tools and products. The fallacy that something incorporating the latest technology is by definition ‘innovative’ is perpetuated by hype and excitement around emerging technologies, in many cases giving them a veneer of credibility before they have a demonstrable evidence base. This is a clear oversight when some of the greatest innovations in healthcare have been remarkably low tech. Mark Slack, consultant gynaecologist and co-founder of <a href="https://cmrsurgical.com/">CMR Surgical</a> was able to provide a striking example of the above.</p><p>The operating theatre is the most common site for adverse surgical incidents, with errors occurring in nearly 15% of all patients globally. International studies suggest that surgery may be responsible for up to 1 million deaths every year, and an additional 7 million postoperative complications [1]. A simple tool implemented in the operating theatre has been able to address these issues and save countless lives. The solution, far from ‘cutting edge’, has had a drastic impact on patient outcomes. The WHO Surgical Safety Checklist (SSC) is now standard practice within the NHS and other healthcare systems and continues to ensure patient safety is protected.</p><p>The development of a new innovation should start with a problem or opportunity (and not a solution). For the WHO, the problem was an unacceptable level of surgical complications, and the SSC was a remarkably simple solution. However the SSC is not a complete solution, and there is always scope to further reduce the complications that may arise from surgical procedures. CMR Surgical are preoccupied with the high level of complications and subsequent costs specifically associated with <em>open</em> surgical procedures. They were aware that minimal access surgery (MAS) was associated with lower rates of incisional hernia, postoperative pain and postoperative infections. However they found that the technical difficulty of this surgical approach was limiting its widespread implementation by surgeons.</p><p>The company began designing and building a surgical robot that would empower surgeons to carry out minimally invasive surgery. As their end-users, surgeons told them they wanted something modular, transportable and adaptable, so CMR’s latest iteration — Versius — is a small, portable, transportable, ergonomic, surgical robot with a 4 axis ‘wrist’ design modelled on human anatomy. Although it is by no means a simple solution to surgical complications, it aims to facilitate a surgical approach that, if adopted, can reduce surgical complications by a halve. It is still early days for the company who are undertaking first in human studies in India, however they expect to be trialling the technology in 11 centres around the world by the end of 2019.</p><p>Surgery is of course an area rife with innovation that goes beyond the work of CMR and other robotic companies. For those looking to innovate in new domains, perhaps one of the last frontiers within healthcare is human longevity. Although we have enjoyed an ever increasing lifespan throughout much of recent history, life expectancy has begun to plateau or even dip in some countries [2]. What’s more, people are becoming increasingly focussed not so much on their lifespan but their ‘healthspan’ — the number of years they can expect to live relatively healthy and disease free. Although the allure of more years on this earth is universally tempting, if these ‘extra’ years are spent bed-bound or becoming increasingly unwell, the value of that time is less clear.</p><p>And so we come to ‘restorative medicine’, the focus of Dr Osman Kibar and his company <a href="https://www.samumed.com/default.aspx">Samumed</a>. Dr Kibar is targeting the ‘Wnt’ signalling pathway which helps guide the differentiation of embryonic and progenitor cell lines into the differentiated cells that make up the different tissues and organs of the human body. Wnt signalling is an important part of maintaining tissue health such that dysregulation of this pathway can lead to tissue breakdown and even cancer. Having developed treatments to target this pathway, they are throwing their technology at a diverse array of conditions to see what sticks.</p><p>Trials for a range of musculoskeletal conditions including osteoarthritis (OA) of the knee, degenerative disc disease and tendinopathy are at a variety of different clinical trial stages. Phase III clinical trials for patients with knee OA have demonstrated cartilage regeneration and increased joint space, whilst compassionate use cases for solid tumours like pancreatic cancer and advanced Alzheimer’s dementia have also had promising results (within the limitations of a single test subject respectively). Clearly the Wnt pathway, which has previously proved difficult to effectively target, holds some degree of promise for achieving true ‘regeneration’ across a variety of different musculoskeletal, oncological and neurological disease types.</p><p>Of course, no discussion about innovation would be complete without talking about artificial intelligence (AI). The term AI is thrown around across the technology sphere with increasing abandon — as a way to generate excitement, interest and most importantly — investment. What people mean when they say ‘AI powered’ is becomingly less clear and the onus is really on the founder or company to explain what type of AI they use and for what purpose (see this <a href="https://medium.com/@Francesco_AI/ai-knowledge-map-how-to-classify-ai-technologies-6c073b969020">article</a> for a helpful diagram on different AI technologies, how they are categorised and for what purposes they are used).</p><p><a href="http://feebris.com/">Feebris</a> see AI as the third iteration of the evolving use of mobile phones in healthcare. Early mobile phones allowed better communication between patients and healthcare services, smart phones have enabled remote consultations and triage, whilst the AI age now promises the possibility of advanced monitoring and even diagnosis through our mobile devices. With respiratory conditions as a leading cause of morbidity and mortality worldwide, and accounting for a huge number of avoidable hospital admissions, Feebris hope their platform will help detect and treat respiratory conditions in the community before they become more serious.</p><p>Through a combination of point of care devices that connect to an AI powered app, Feebris employ machine learning algorithms to extract useful data from these devices and identify patterns specific to different respiratory diseases. Based on the result, they can provide triage recommendations to patients and healthcare professionals. As with similar companies working in disease identification, Feebris is a decision support tool and not a diagnostic device (at least until they await class 2 medical device certification), so healthcare professionals utilising their platform always have the option to override any outcome from the app should they think it inappropriate or inaccurate.</p><p>Their aim emulates the new age maxim that healthcare should move from a reactive model to a proactive model, where interventions are implemented early before people get (seriously) unwell. The outcome is less demand on acute medical services and a reduction in morbidity and mortality.</p><p>Also aiming to reduce pressure on in-person healthcare services are <a href="http://www.arthronica.com/ai-solutions">Arthronica</a>, another AI startup looking to disrupt arthritis assessment and management. Unlike Feebris, they are using ‘AI based visual search’ to monitor patients with musculoskeletal and rheumatological conditions. Effectively, they can take an image or a video of a patient’s hand and accurately assess joint range of motion, contact forces (e.g. between fingers), and joint swelling — all without the use of wearables or point of care devices. The company is supported by <a href="http://medtechsuperconnector.com/">MedTech Superconnecto</a>r (an incubator that receives funding by Research England), and funded by Entrepreneur First, an international talent investor scheme. To date they have raised hundreds of thousands in funding and are currently testing their technology on 20,000 patients in order to further improve their technology and establish it’s role in treatment pathways.</p><p>At the start of this article I emphasised how innovation doesn’t always have to be high tech. However much of the preceding discussion has revolved around companies involved in robotics, pharmaceuticals and artificial intelligence. The conference featured many other inspiring and interesting companies and individuals, some of which had remarkably simple solutions for far-reaching problems. Seb Tucknott, a designer with ulcerative colitis, founded <a href="https://www.ibdrelief.com/">IBD Relief</a>, an online resource to ensure people with inflammatory bowel disease have access to high quality and helpful content to guide them through their illness. While Nuala Burke, Clinical Lead for <a href="https://www.walkwithpath.com/">Walk with Path</a> told the story of how her company was able to help sufferers of Parkinson’s disease by attaching laser prompters to the front of shoes — providing the visual cues that these individuals need in order to walk unimpeded.</p><p>Ultimately, all those who presented had found, or were working on, innovative solutions for important problems within medicine and healthcare. For all the progress in technology however, we would do well to remember that sometimes the greatest innovations are those that don’t involve frontier technologies or millions of pounds of investment. Just like a series of checks, listed on a page, that makes up the WHO SSC — the right tool applied in the right setting will always provide beneficial outcomes, no matter how technologically advanced it might be.</p><p>References</p><ol><li><a href="https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(15)60160-X.pdf">https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(15)60160-X.pdf</a></li><li><a href="https://www.theguardian.com/society/2019/jun/23/why-is-life-expectancy-falling">https://www.theguardian.com/society/2019/jun/23/why-is-life-expectancy-falling</a></li></ol><p>If you enjoyed this article and want to get in touch, find me on Twitter <a href="http://twitter.com/sandycewright">@SandyCEWright</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7a4f93783376" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Recent Developments in AI & Digital Health]]></title>
            <link>https://medium.com/@sandywright/recent-developments-in-ai-digital-health-e80491fc742f?source=rss-d611815f6ac4------2</link>
            <guid isPermaLink="false">https://medium.com/p/e80491fc742f</guid>
            <category><![CDATA[health-technology]]></category>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[artificial-intelligence]]></category>
            <category><![CDATA[deep-learning]]></category>
            <category><![CDATA[digital-health]]></category>
            <dc:creator><![CDATA[Sandy Wright]]></dc:creator>
            <pubDate>Mon, 25 Mar 2019 20:42:21 GMT</pubDate>
            <atom:updated>2019-03-26T21:22:03.167Z</atom:updated>
            <content:encoded><![CDATA[<blockquote>The Royal Society of Medicine’s Digital Health Section holds regular meetings on the latest developments in digital health. On February 26th 2019, attendees convened on the RSM’s home in central London to hear from prominent speakers on the subject of Artificial Intelligence (AI) in healthcare. Entitled ‘Recent Developments in AI &amp; Digital Health’, the meeting explored the application of AI in research, diagnostics and drug discovery. To watch the summary videos of the conference talks, click <a href="https://www.youtube.com/user/RoyalSocietyMedicine">here</a>. Catch up with the Twitter discussion from the event <a href="https://rsm.ac/2WmPEvN">here</a>.</blockquote><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*iEqbakgmjZnBwDT8dnqBsw.jpeg" /><figcaption>The Royal Society of Medicine — 1 Wimpole Street, London</figcaption></figure><p>Turns out AI is a popular topic. Although the Digital Health Section of the RSM is well known for delivering high quality events and conferences, for this AI-themed event we found ourselves moving into a larger venue and releasing more tickets to meet demand. Clearly there’s a strong appetite amongst healthcare and industry professionals to learn more about this emerging technology. Or perhaps there’s a prevailing sense of scepticism about how much AI can really ‘revolutionise’ healthcare.</p><p>For all the talk of machine learning algorithms, natural language processing and synthetic data, I felt a strong disconnect between the solutions on show and their proposed implementation within an institution that is yet to move away from archaic technologies like pager systems and fax machines. Nevertheless, the discussions and ideas shared on the day went some way to addressing preoccupations about how AI might shape the future of healthcare both in the UK and on a global scale. Included here is a brief summary of the conclusions drawn from the day by the speakers who contributed to the conversation. You can see a full list of the speakers and their presentations <a href="https://rsm.ac/2HFqS6S">here</a>.</p><p>According to a Lancet <a href="https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(15)70115-4/fulltext">report</a> from 2015, 5 billion people in the world lack access to safe and affordable surgery. In order to meet this demand, the research suggests an additional 2.2 million surgeons are required over the next 15 years. The Royal College of Radiologists published a <a href="https://www.rcr.ac.uk/publication/breast-imaging-and-diagnostic-workforce-united-kingdom">report</a> in 2016 that showed 25% of breast screening units are understaffed in the UK, with 13% of breast radiologist posts lying vacant. It is issues like these that companies like Digital Surgery and Kheiron Medical are attempting to solve in surgery and breast cancer screening respectively. Across the board, the medical workforce has failed to scale in order to meet ever rising public demand. Could AI technologies be a part of the solution? In the case of Digital Surgery, it’s about providing a suite of tools that deliver an end to end surgical support solution from education to operation. Whereas for Kheiron Medical, the integration of a deep learning product into the breast cancer screening workflow could go some way to making up for the lack of radiologists.</p><p>The initial training of Kheiron’s deep learning technology used mammograms from Hungarian citizens. Although the company are now testing the technology against existing scans from trusts in the UK, we have to wonder whether there should be more collaboration between institutions like the NHS and companies like this who want to explore novel tools for providing better workflows and patient care. Unfortunately we live in a world where the rate of technological advances is far outpacing regulatory oversight. There is a culture clash between the ‘move fast and break things’ ethos of the tech world vs the safety-first model of modern public healthcare delivery that can make collaboration and cooperation difficult.</p><p>Perhaps then it is the role of research hospitals like UCLH to provide the platform for testing and integration of novel technologies into mainstream healthcare. In 2018, UCLH <a href="https://www.uclh.nhs.uk/News/Pages/RevolutionisinghealthcarewithAI.aspx">announced</a> a new partnership with The Alan Turing Institute that aims to bring together data science and artificial intelligence to support clinical decision making. This new partnership ensures the right ingredients are present to develop a successful research hospital. These include specialised facilities, translational expertise and academic training. Aside from working towards discovering new treatments, developing partnerships in the public and private sector, and ultimately creating new companies, the key focus of institutions like this should be to figure out how to successfully operationalise AI.</p><p>Many may be concerned about the prospect of increasing cooperation and integration of the private and public sector in the development of novel AI technologies. Phrases such as ‘privatisation by the back door’ are thrown around perhaps without due consideration for the opportunities such collaboration can bring. Nevertheless, the NHS needs to better understand the value of the health data it collects and currently under utilises, and use this as leverage to ensure it can establish fair commercial models between the NHS, patients and industry. Indeed, the patient voice is key to consider as we move forward with AI.</p><p>One of the problems with any new technology is the assumption that it is in itself a solution. Whether it’s AI, VR or blockchain, many companies and entrepreneurs look to see where they can be applied rather than using the initial problem as the starting point. With health data and the value it contains, it would be unwise to throw a myriad of new technologies at it simply to see what sticks. The right approach is to start with the problem or the user/patient need and let that guide the development of the solution. Perhaps it requires non of the technologies above. We can’t just assume that digital technologies will always make processes faster and more efficient. In some cases it simply won’t.</p><p>So while we explore the opportunities that AI might provide healthcare, we need to keep patients at the heart of the process and understand that it’s not just about educating them about these new technologies, but bringing them along for the journey of discovery. This is a journey that will inevitably require iteration, failure and mistakes. Perhaps the greatest threat to AI in healthcare would be developing the regulatory and governance models that guide the use of health data to develop these technologies, without integrating patient perspectives into the process.</p><p>The model for co-opting patients into the development process is best illustrated in low and middle income countries where AI is aiming to improve access to healthcare. Both Babylon and Ada Health are deploying digital technologies in resource-poor settings in order to make healthcare more accessible. The lessons from these companies is that solutions and products cannot simply be forced on a population through a top-down approach. The context of communities at the local level is vitally important to understand. Existing healthcare structures need to be supported and local healthcare organisations need to be partnered with in order to gain trust and demonstrate credibility to end-users. The AI itself needs to be sophisticated enough to understand the nuance of culture and language which might affect how someone interacts with a chatbot and gains accurate medical advice for example.</p><p>One of the main conclusions from the conference was the idea that AI can’t solve the structural problems that currently exist in healthcare. Although there was much promise from the companies and institutions on show during the day’s presentations about the future, there is much that can be done now to ensure that the basics are done right in order to make healthcare faster, better and cheaper. This might be in the domains of electronic health records, the coding of quality health data and making digital health systems interoperable.</p><p>Nevertheless, a comment about AI that has stuck with me speaks to one of the key outcomes we should push for when implementing these technologies. Arguably the greatest potential of AI in healthcare is providing the ‘gift of time’ — allowing healthcare professionals to spend more time actually caring for patients (arguably one thing that an AI will never be able to do) and less time burdened with bureaucracy and administrative tasks. It might be hard for your average GP to see how AI is going to help them manage the social aspects of care — a homeless patient with multiple co-morbidities or an isolated elderly person with worsening dementia — but it can at least aim to give them the opportunity to be the compassionate, holistic medical practitioner they were trained to be.</p><p>There was a call during the conference to rename Artificial Intelligence to something more accessible and understandable. Augmented Intelligence was proposed (at least it preserves the acronym). Whatever we ultimately decide to call it, it was clear from the presentations that AI is here to stay. Whether we believe the hype or not, AI is being integrated into the plans and processes that will define the future of health in this country. We should all strive to contribute to the conversation.</p><p>If you enjoyed this article and want to get in touch, find me on Twitter <a href="http://twitter.com/sandycewright">@SandyCEWright</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e80491fc742f" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Health data. Who owns it?]]></title>
            <link>https://medium.com/@sandywright/health-data-who-owns-it-d083a9d1d3d4?source=rss-d611815f6ac4------2</link>
            <guid isPermaLink="false">https://medium.com/p/d083a9d1d3d4</guid>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[data]]></category>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[privacy]]></category>
            <category><![CDATA[technology]]></category>
            <dc:creator><![CDATA[Sandy Wright]]></dc:creator>
            <pubDate>Sun, 14 Oct 2018 21:20:47 GMT</pubDate>
            <atom:updated>2018-10-14T21:20:47.865Z</atom:updated>
            <content:encoded><![CDATA[<blockquote>The Royal Society of Medicine’s Digital Health Section holds regular meetings on the latest developments in digital health. On September 24th 2018, attendees convened on the RSM’s home in central London to hear from prominent speakers on the subject of health data. Entitled ‘Health data: Who owns it and how to keep it safe’, the meeting explored the current issues and ethics surrounding the use and misuse of health data. To find out about upcoming Digital Health events at the RSM, click <a href="https://www.rsm.ac.uk/sections/sections-and-networks-list/digital-health-section.aspx">here</a>.</blockquote><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*iEqbakgmjZnBwDT8dnqBsw.jpeg" /><figcaption>The Royal Society of Medicine — 1 Wimpole Street, London</figcaption></figure><p>Digital health events do not normally feature kettles. Let alone smart kettles. But the attention of the audience was trained on this piece of stainless steel perched precariously on the speaker’s podium. Whilst many may have questioned the value of a kettle you can control from your phone, Ken Munro, ethical hacker and security entrepreneur, was demonstrating the risk of bringing devices like this into your home.</p><p>Minimising his presentation slides, Ken swiftly pulled up a command line on his computer, accessed the kettle’s operating system, and successfully retrieved the unencrypted wi-fi password to which the kettle was connected. He explained how the ‘smart’ kettle was an easy way for any hacker to gain access to a home network and the devices and web traffic contained within it. Ken’s message was blunt. Medical IoT devices are no different from consumer focussed ‘smart’ products and suffer from the same security vulnerabilities. Theoretically, the same techniques could be used to take control of someone’s cardiac pacemaker or insulin pump.</p><p>It was a sobering start to a day of talks that were to focus on the topic of health data and ownership. But before we could broach the subject of ‘ownership’, David Ferbrache, technical director at KPMG, had revealed the extent to which our health data had already been stolen. According to <a href="https://www.axios.com/health-care-data-privacy-hacking-9fff9d57-789b-481c-a4bb-03609f2307c5.html">Axios</a>, over 175 million healthcare records have been hacked since 2010. There is currently a glut of health data on the dark web, driving down the price of individual health records for those who want to use them for illicit purposes. As David went on to explain, health records are traded and sold just like any other commodity, with discounts for bulk purchases and try-before-you-buy agreements.</p><p>So what is the key to preventing further hacks? According to Professor Paul Dorey, visiting Professor at Royal Holloway and founder of CSO Confidential, it’s about empowering people and creating a ‘just’ culture . During his presentation, he argued that people are wrongly labelled as the weakest link in data security. In fact, it is poor processes and unreasonable expectations that drive people towards workarounds that ultimately put data at risk. If companies can create an environment where workers feel comfortable to talk about security openly and assist with the development of cybersecurity protocols, data will ultimately be better protected.</p><p>The citizens of Estonia are a cohort who have been co-opted into the development of their digital democracy. Almost all public services in Estonia are administered or accessible online - making it one of the most advanced digital societies in the world. In the 2015 general election over 30% of votes were cast online. Dr Ain Aaviksoo, Digital Health Evangelist and former CIIO of the Ministry of Social Affairs in Estonia told the conference how Estonia had implemented blockchain as a electronic health record solution before blockchain became the heralded technology it is today. Estonian companies like Guardtime have helped the country develop sophisticated blockchain technologies such as <a href="https://e-estonia.com/solutions/security-and-safety/ksi-blockchain/">KSI</a> (Keyless Signature Infrastructure) that ensures data is authentic, private and safe.</p><p>Having explored the current vulnerabilities of health data, the conference turned to focus on the question of ‘who owns data’. No discussion on this topic would be complete without a healthy recap of EUGDPR and a review of the DeepMind Royal Free ‘Streams’ app controversy. Helpfully, Linklaters, the law firm who carried out the <a href="http://s3-eu-west-1.amazonaws.com/files.royalfree.nhs.uk/Reporting/Streams_Report.pdf">third party audit</a> of ‘Streams’, were on hand at the conference to explore issues around data compliance.</p><p>To summarise, in 2015 the Royal Free hospital began to work with DeepMind on a project to help with the detection of Acute Kidney Injury. As the project started to gain public attention, the hospital was investigated by the Information Commissioner who raised concerns about the agreement between the two institutions and the degree to which patients had been informed about the joint project. The independent review by Linklaters found that the Royal Free’s use of streams was lawful, and concluded that Deepmind had only used patient data for the Streams project. Specifically, patient data was not used to train an AI algorithm (in fact the Streams project used a comparatively simple decision tree tool), and both institutions were deemed to have taken appropriate measures to protect sensitive patient data.</p><p>The issue, then, was one of communication. Poorly communicating with patients on how their data will be used. And in many ways, this is what EUGDPR has set out to improve. As our inboxes filled up in May with emails from every company we’d ever given our email address to, we were bombarded with their new-found policies on how our data was going to be collected and processed. We as consumers now had the right to portability and erasure of data, and companies had new requirements to brush up on their privacy notices and appoint data protection officers or else face significant fines.</p><p>The driving force behind EUGDPR is to empower consumers to take control of their data and ensure those who act as custodians of our data are subject to the appropriate checks and balances. But that doesn’t help us understand who actually ‘owns’ this data. John Rumbold, Senior Research Fellow at Nottingham Trent University, highlighted the case of ‘Oxford vs Moss’ during his presentation on data ownership in biomedical research. In this seminal case, a university student stole a forthcoming exam paper with the intention of returning the document having used the information to cheat on his exam. The court ruled that the confidential information contained within the exam paper could not be classified as property and therefore was incapable of being stolen (according to the Theft Act 1968). John concluded that if data isn’t technically classed as property, it is therefore impossible to own it.</p><p>The conference put forward the idea of individuals having ‘quasi-ownership’ over their data. GDPR has given us certain rights (to portability and erasure etc), whilst those who control and process our data also maintain certain data rights to use that data in appropriate ways. This was certainly the argument put forward by Luk Arbuckle, Chief Methodologist at IQVIA. But in the realm of health research, it is the role of the data controllers to ensure the appropriate risk based anonymisation is put in place to both satisfy GDPR whilst ensuring data is still a useful utility in health research.</p><p>When we talk about health data, many may think about specific health parameters captured at specific time points. Blood test results recorded when we go to hospital, blood pressure measurements when we visit our family doctor. But what about lesser contemplated forms of data? Data gathered from voice or facial recognition software for example. What about the data obtained from new types of medications that can track when we’ve actually ingested a tablet? These are not problems of the future. They are potential issues that are with us now.</p><p>Lienkie Diedericks from King’s College London discussed the ethical implications of the emerging field of ‘digiceuticals’. <a href="https://www.proteus.com/">Proteus Digital Health</a> in the US have developed a novel version of the antipsychotic medication — aripiprazole. Using their proprietary technology, the ingestion of the medication can be tracked via a smart patch on the patient’s skin and the data relayed to a mobile application. In effect, the patient’s compliance with their medication can be tracked and quantified.</p><p>This novel intervention digitises pharmacology. It shifts the focus away from the product’s interaction with the human body towards the consumer’s behaviour in relation to medication adherence and compliance. Although technological developments like this are being mooted as a way of giving patient’s more ‘control’, it raises the uncomfortable question of how pharmaceutical companies will use this data. Will they intervene if compliance is poor? Will health insurers have access to the compliance data? In the specific case of aripiprazole — is it ethical to digitally track drug compliance in a population who are taking a medication for a condition that already predisposes them to suspicion and paranoia? Lienkie’s conclusion is that regulation lags way behind the current technological developments.</p><p>As the conference wrapped up, there was a prevailing conclusion that the regulatory and ethical considerations were not keeping pace with current technological advancements in the healthcare space. Although many of the speakers highlighted the value of patient data in developing novel technologies and ultimately improving patient outcomes, ‘personal data’ is a term that has significant emotive connotations for a large proportion of general public. Whether this scepticism and trepidation serves as an impediment to further advancements or acts as a healthy checkpoint to rogue players, the answer is still unclear. The argument of data ownership is one that is likely to continue for many years to come.</p><p>If you enjoyed this article and want to get in touch, find me on Twitter <a href="http://twitter.com/sandycewright">@SandyCEWright</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=d083a9d1d3d4" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>